GlaxoSmithKline Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
GLAXO
Pharmaceuticals
Screen GlaxoSmithKline Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹2483.30
▲
27.10 (1.10%)
Share Price BSE
₹2482.25
▲
25.20 (1.03%)
Market Cap
₹41,606.12 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
24.51
EPS (TTM)
₹54.76
Dividend Yield
2.19%
Debt to Equity
0.01
52W High
₹3466.20
52W Low
₹1956.20
Operating Margin
34.00%
Profit Margin
25.91%
Revenue (TTM)
₹1,015.00
EBITDA
₹374.00
Net Income
₹263.00
Total Assets
₹4,108.00
Total Equity
₹1,951.00
GlaxoSmithKline Pharmaceuticals Share Price History - Stock Screener Chart
Screen GLAXO historical share price movements with interactive charts. Analyze price trends and patterns.
GlaxoSmithKline Pharmaceuticals Company Profile - Fundamental Screener
Screen GlaxoSmithKline Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GLAXO shares.
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Renu S Karnad
ISIN
INE159A01016
Website
https://www.gsk-india.com
GlaxoSmithKline Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GLAXO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 |
| Current Assets | 3,410 | 2,798 | 2,494 | 3,708 | 2,203 | 1,775 | 2,010 | 2,186 | 1,674 | 2,174 |
| Fixed Assets | 284 | 321 | 330 | 331 | 387 | 758 | 432 | 325 | 258 | 210 |
| Liabilities | ||||||||||
| Total Liabilities | 4,108 | 3,557 | 3,327 | 4,633 | 3,115 | 3,136 | 3,911 | 3,948 | 3,004 | 3,055 |
| Current Liabilities | 252 | 254 | 259 | 272 | 282 | 291 | 317 | 290 | 277 | 292 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,951 | 1,778 | 1,741 | 2,663 | 1,478 | 1,821 | 2,140 | 2,057 | 2,007 | 2,183 |
| Share Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 85 | 85 | 85 |
| Reserves & Surplus | 1,782 | 1,608 | 1,572 | 2,494 | 1,309 | 1,651 | 1,970 | 1,973 | 1,922 | 2,099 |
GlaxoSmithKline Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Intrinsic ValueScreen GLAXO income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,015 | 849 | 1,016 | 962 | 850 | 1,050 | 985 | 826 | 815 | 985 | 833 | 2,132 | 776 | 939 | 826 |
| Expenses | 641 | 554 | 644 | 673 | 584 | 689 | 658 | 618 | 618 | 668 | 751 | 634 | 596 | 660 | 585 |
| EBITDA | 374 | 295 | 372 | 290 | 266 | 361 | 327 | 208 | 198 | 318 | 83 | 1,497 | 180 | 279 | 241 |
| Operating Profit % | 34.00% | 31.00% | 34.00% | 28.00% | 28.00% | 32.00% | 31.00% | 22.00% | 19.00% | 30.00% | 7.00% | 22.00% | 20.00% | 28.00% | 27.00% |
| Depreciation | 15 | 16 | 17 | 18 | 16 | 17 | 19 | 17 | 16 | 18 | 17 | 15 | 16 | 16 | 16 |
| Interest | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 359 | 279 | 354 | 271 | 249 | 344 | 308 | 190 | 181 | 299 | 65 | 1,482 | 163 | 262 | 224 |
| Tax | 96 | 74 | 97 | 76 | 67 | 91 | 78 | 57 | 49 | 82 | 20 | 263 | 44 | 69 | 60 |
| Net Profit | 263 | 205 | 258 | 195 | 182 | 253 | 230 | 133 | 132 | 218 | 46 | 1,219 | 119 | 193 | 165 |
| EPS | 15.52 | 12.10 | 15.07 | 11.37 | 10.76 | 14.67 | 13.57 | 7.41 | 7.04 | 12.84 | 9.89 | 71.96 | 7.04 | 11.42 | 9.71 |
GlaxoSmithKline Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GLAXO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,290 | 582 | 484 | 811 | 578 | 491 | 410 | 473 | 234 | 139 |
| Investing Activities | -46 | 9 | 808 | -406 | 418 | -57 | -153 | -104 | 301 | 499 |
| Financing Activities | -769 | -562 | -1,543 | -524 | -696 | -428 | -358 | -307 | -511 | -638 |
| Net Cash Flow | 475 | 29 | -251 | -119 | 300 | 6 | -102 | 62 | 24 | 0 |
Screen GLAXO shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 4.52% | 4.89% | 4.80% | 3.48% | 4.02% | 4.36% | 4.50% | 0.00% |
| DII Holding | 7.79% | 7.70% | 7.75% | 7.90% | 7.50% | 7.34% | 7.30% | 10.30% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.60% | 10.32% | 10.34% | 11.27% | 11.15% | 10.97% | 10.96% | 10.54% |
| Other Holding | 2.09% | 2.09% | 2.11% | 2.35% | 2.33% | 2.33% | 2.23% | 4.16% |
| Shareholder Count | 121,885 | 123,629 | 122,904 | 118,994 | 118,515 | 119,228 | 119,625 | 120,415 |
GlaxoSmithKline Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen GLAXO dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹54.00 | 2.18% |
| 2024-March | ₹32.00 | 1.11% |
| 2023-March | ₹32.00 | 1.64% |
| 2022-March | ₹90.00 | 7.05% |
| 2021-March | ₹30.00 | 1.80% |
| 2020-March | ₹40.00 | 2.78% |
| 2019-March | ₹20.00 | 1.59% |
| 2018-March | ₹35.00 | 2.70% |
| 2017-March | ₹30.00 | 2.87% |
GlaxoSmithKline Pharmaceuticals Index Membership - Market Screener Classification
Screen GLAXO by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
GlaxoSmithKline Pharmaceuticals Market Events Screener - Corporate Actions
Screen GLAXO market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Bonus | 1:1 | -0.11% | ||
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -3.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -3.21% |
| 2025-06-27 | 2025-06-27 | Annual General Meeting | NA | 21.34% |
| 2025-05-30 | 2025-05-30 | Dividend | ₹ 42.00 /share | 19.92% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | -7.08% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -3.77% |
| 2024-11-07 | 2024-11-07 | Dividend | ₹ 12.00 /share | -0.47% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | 0.52% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | 32.30% |
| 2024-05-31 | 2024-05-31 | Dividend | ₹ 32.00 /share | 28.12% |
| 2023-06-30 | 2023-06-30 | Dividend | ₹ 32.00 /share | 11.53% |
| 2022-07-26 | 2022-07-26 | Annual General Meeting | NA | 0.04% |
| 2022-07-07 | 2022-07-08 | Dividend | ₹ 60.00 /share | 0.84% |
| 2022-07-07 | 2022-07-08 | Dividend | ₹ 30.00 /share | 0.84% |
GlaxoSmithKline Pharmaceuticals Competitors Screener - Peer Comparison
Screen GLAXO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 410,790 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 168,798 | 68.31 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,095 | 60.76 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 121,408 | 22.46 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 104,496 | 18.49 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 95,457 | 22.19 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 91,769 | 18.30 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 89,612 | 51.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,308 | 20.05 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 64,906 | 27.31 | 13,458 | 3.70% | 2,216 | 41.76 |
GlaxoSmithKline Pharmaceuticals Company Announcements - News Screener
Screen GLAXO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-07 | Disclosure Under Regulation 30 | View |
| 2026-01-07 | Volume Movement Letter | View |
| 2026-01-07 | Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd | - |
| 2025-12-30 | Closure of Trading Window | View |
| 2025-12-29 | Disclosure Under Regulation 30 | View |
| 2025-12-18 | Disclosure Under Regulation 30 | View |
| 2025-12-12 | Disclosure Under Regulation 30 | View |
| 2025-11-19 | Disclosure Under Regulation 30 | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-11-06 | Results Ended Quater September 2025 | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-06 | Board Meeting Outcome for Outcome | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-10-27 | Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter & Half Year Ended 30Th September 2025. | View |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |